ANAPTYSBIO
Updated 43 days ago
- Age: 11 years
- ID: 16274069/131
10770 Wateridge Circle Suite 210 San Diego, CA 92121-5801
Anaptys is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics. We are developing immune cell modulators, including two checkpoint agonists for autoimmune and inflammatory disease: rosnilimab, our PD-1 agonist, in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis; and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of atopic dermatitis. Our preclinical immune cell modulator portfolio includes ANB033, an anti-CD122 antagonist antibody, and ANB101, a BDCA2 modulator antibody, for the treatment of autoimmune and inflammatory diseases... In addition, Anaptys has developed two cytokine antagonists available for out-licensing: imsidolimab, an anti-IL-36R antagonist, in Phase 3 for the treatment of generalized pustular psoriasis, or GPP, and etokimab, an anti-IL-33 antagonist for the treatment of respiratory disorders that is Phase 2/3 ready. Anaptys has also..
Also known as: Anaptys, AnaptysBio, Inc.
Associated domains: anaptisbio.com, anaptsybio.com, anaptsysbio.com, anaptys.bio, anaptysbio.org, anaptysbiotrials.com, anapytsbio.com, anatpysbio.com